HeidelbergCapital is an independent Private Equity Funds Group, specialising in Secondary Direct Investments, e.g. the acquisition of shareholdings in companies previously held by private equity/venture capital funds or banks.
News
05.02.2020
vasopharm completes patient enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
31.01.2018
4SC: Positive DSMB safety review of 4SC’s pivotal RESMAIN study of resminostat in CTCL
25.01.2018
Nanogate SE Expects 2018 Operating Result (EBITDA) of More Than EUR 24 Million and Sales of at Least EUR 220 Million
22.01.2018
4SC AG strengthens patent protection for its Hedgehog/GLI signaling inhibitor 4SC-208
10.01.2018
Nanogate SE: Market Launch of New Technology Platform to Replace Stainless Steel
20.12.2017
4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency
About us
HeidelbergCapital was founded mid 2007. The company is jointly managed by Dr. Clemens Doppler and Prof. Dr. Martin Weiblen, former Managing Director of a multi-billion family office in London/U.K. and advisor to several Life Science-Funds. Dr. Clemens Doppler is a former Partner at 3i, the British Private Equity Group. The New York based Private Equity Investor Auda has committed c150m USD for the first fund, HeidelbergCapital Private Equity Fund I.
The portfolio of HeidelbergCapital ranges from investments in later stage venture companies with a proven business model to established mid-size operations. As an active partner, HeidelbergCapital supports the companies in strategic business decisions, but also provides, where appropriate, funding for further growth.
